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ORIGINAL ARTICLETraumatic Endotheliopathy: A Prospective Observational
rely Injured PatientsStudy of 424 SevePa¨r I. Johansson, MD, DMSc, MPA,y Hanne H. Henriksen, BSc, Jakob Stensballe, MD, PhD,z
Mikkel Gybel-Brask, MD, Jessica C. Cardenas, PhD,y Lisa A. Baer, BSc,y Bryan A. Cotton, MD, MPH,y
John B. Holcomb, MD,y Charles E. Wade, PhD,y and Sisse R. Ostrowski, MD, PhD, DMScObjective: Investigate and confirm the association between sympathoadrenal
activation, endotheliopathy and poor outcome in trauma patients.
Background: The association between sympathoadrenal activation, endo-
theliopathy, and poor outcome in trauma has only been demonstrated in
smaller patient cohorts and animal models but needs confirmation in a large
independent patient cohort.
Methods: Prospective observational study of 424 trauma patients admitted to
a level 1 TraumaCenter. Admission plasma levels of catecholamines (adrenaline,
noradrenaline) andbiomarkers reflectingendothelial damage (syndecan-1, throm-
bomodulin, and sE-selectin) were measured and demography, injury type and
severity, physiology, treatment, and mortality up till 28 days were recorded.
Results: Patients had a median ISS of 17 with 72% suffering from blunt
injury. Adrenaline and noradrenaline correlated with syndecan-1 (r ¼ 0.38,
P<0.001 and r ¼ 0.23, P<0.001, respectively) but adrenaline was the only
independent predictor of syndecan-1 bymultiple linear regression adjusted for
age, injury severity score, Glascow Coma Scale, systolic blood pressure, base
excess, platelet count, hemoglobin, prehospital plasma, and prehospital fluids
(100 pg/mL higher adrenaline predicted 2.75 ng/mL higher syndecan-1,
P < 0.001). By Cox analyses adjusted for age, sex, injury severity score,
Glascow Coma Scale, base excess, platelet count and hemoglobin, adrenaline,
and syndecan-1 were the only independent predictors of both < 24-hours, 7-
day and 28-day mortality (all P < 0.05). Furthermore, noradrenaline was an
independent predictor of < 24-hours mortality and thrombomodulin was an
independent predictor of 7-day and 28-day mortality (all P < 0.05).
Conclusions: We confirmed that sympathoadrenal activation was strongly
and independently associated with endothelial glycocalyx and cell damage
(ie, endotheliopathy) and furthermore that sympathoadrenal activation and
endotheliopathy were independent predictors of mortality in trauma patients.
Keywords: endotheliopathy, mortality, syndecan-1, thrombomodulin, trauma
(Ann Surg 2017;265:597–603)
T rauma is a major cause of death and disability worldwide anddespite the introduction of damage control resuscitation1
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Surgery  Volume 265, Number 3, March 2017patients present with laboratory defined coagulopathy upon admis-
sion, and this is associated with a three to fourfold increase in
mortality.3 In the literature, laboratory coagulopathy also designated
trauma induced coagulopathy (TIC) is described as an over activation
of the protein C pathway accompanied by hyperfibrinolysis4 or
as representing the hemorrhagic phenotype of disseminated intra-
vascular coagulation.5 Common for both these explanations is that
they are based on measuring concentrations of pro- and antico-
agulant coagulation factors, platelet count, and fibrin degradation
products.
The introduction of the cell based model of hemostasis in the
late 1990 s taught us that to adequately assess hemostatic compe-
tence whole blood that includes blood cellular elements should be
used6 and consequently, assays reflecting this were required. When
studying trauma patients at admission with whole blood thrombe-
lastography (TEG), we found that with increasing injury severity,
the hemostatic profile became progressively more hypocoagulable
and hyperfibrinolytic, which seemed counterintuitive given the
substantial risk of exsanguination these patients faced.7 To fully
comprehend these findings, we speculated that the endothelium
should also be included as a pivotal part of the vascular compartment
and we hypothesized that the hemostatic changes observed in whole
blood represented an evolutionary adapted response to a potential
life-threatening condition.8 The vascular endothelium comprises a
single layer of cells that lines every vessel in the body, covers a total
surface area of 5000 m2 and has a total weight of 1 kg.9 On the
luminal part of the endothelium lays the endothelial glycocalyx, a
0.2 to 1mm thick negatively charged antiadhesive and anticoagulant
carbohydrate-rich surface layer that protects the endothelium
and maintains vascular barrier function.10–12 The endothelium is
instrumental for balancing hemostasis and for maintaining
the homeostasis between the circulating blood and the extravascular
space/surrounding tissues.13,14 Furthermore, given the immediate
nature of changes in hemostatic competence in severely injured
trauma patients we further speculated that activation of the sym-
pathoadrenal activation, with release of large amounts of catechol-
amines was an important driver of this condition.8
In independent, but small, studies of trauma patients, we
found that (i) high circulating syndecan-1, a marker of endothelial
glycocalyx degradation,15 was associated with inflammation, hypo-
coagulability, and increased mortality;16 (ii) the trauma-induced
catecholamine surgewas closely associated with biomarkers of tissue
and endothelial damage, glycocalyx degradation, hypocoagulability
including hyperfibrinolysis and independently predicted mortality;17
and (iii) the syndecan-1 levels decreased after resuscitation with
plasma.18 We also found that an important determinant of the
hypocoagulability observed by whole blood TEG, in these patients,
was because of endogenous heparinization induced by the constitu-
ents released from the glycocalyx in response to the trauma and
shock.19 Collectively, these data indicated that endothelial damage
and/or dysfunction significantly contributed to outcome and that
sympathoadrenal activation was an important driver of early shock
20wer Health, Inc. All rights reserved.
induced coagulopathy.
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along with red blood cells (RBCs) to trauma patients with severe
hemorrhage, not only reduced early deaths caused by exsanguina-
tion21 but also led to a reduction in development of multiple organ
failure.22 Interestingly, Kozar et al23 found in a rat model of
hemorrhagic shock that resuscitation with plasma, as opposed to
normal saline, had an endothelial- and glycocalyx rejuvenating effect
related to increased mRNA levels of Syndecan-1 in the endothelial
cells. More recently, adiponectin was identified as an important
component in FFP to attenuate endothelial damage and improve
lung vascular barrier function in mice after shock and resuscitation
and collectively, these data suggest a pivotal role of the endothelium
for outcome in trauma patients with hemorrhagic shock.24,25
The aim of the current study was therefore to validate and
confirm our preliminary findings presented above in a larger, and
independent, cohort of trauma patients and to more comprehensively
characterize the endothelium by analyzing also soluble thrombomo-
dulin (sTM), an endothelial cell damage marker, and soluble
E-selectin (sE-selectin), an endothelial cell activation marker, which
both have been significantly associated with poor outcome in patients
with other types of acute critical illness.26–28
METHODS
Setting and Patients
This prospective observational study was conducted under an
approved Institutional Review Board (IRB) (Universal Study, HSC-
GEN-12–0059), which included all adult trauma patients (16 yrs)
at the highest level of activation at Memorial Hermann Hospital
Texas Medical Center (MHH-TMC). The criteria for highest acti-
vation include: Glasgow Coma Score 10, heart rate >120 beats
per minute, systolic blood pressure90, respiratory rate<10 or> 29
per minute, intubation, penetrating injury to torso, groin, head or
neck, amputation proximal to ankle or wrist, paraplegia, quadriple-
gia, uncontrolled external hemorrhage, fracture to pelvis or two or
more long bone fractures, and receiving blood en route. The study
took place over 18 months fromMarch 2012 to September 2013. This
was an opportunistic prospective study that ran parallel to three other
clinical studies at MHH-TMC; patients admitted to the other studies
were not included in this analysis. Samples were collected when
research staff was not directly involved in the other studies and
available to process the samples. The IRB approval was obtained for
delayed consent, obtained from the patient or their legally authorized
representative within 72 hours of admission, or as soon as possible.
For patients who were discharged or died within 24 hours of admis-
sion, a waiver of consent was obtained. If consent could not
be obtained, the patient was excluded from the study and their
blood samples destroyed. The study excluded pregnant women
and prisoners.
In the current study, plasma biomarkers from a total of
561 patients were investigated. Of these, only patients suffering
from blunt or penetrating injury were included with the requirement
that data on ISS and adrenaline, noradrenaline, syndecan-1, and
thrombomodulin were available. This excluded burn injury patients
(n¼ 64) and an additional 73 patients [ie, nontrauma (n¼ 2), missing
ISS (n ¼ 42), and missing biomarkers (n ¼ 29)]. The excluded
nonburn injury patients (n ¼ 73) did not differ significantly from
the 424 included patients with regard to age median 43 years
(interquartile range, IQR 27–55), sex (73% males), and <24-hours,
7-day, and 28-day mortality (4%, 14%, and 15%, respectively).
Clinical Data and Blood Samples
Information on baseline demography, clinical, physiologic, Copyright © 2016 Wolters Kluw
and laboratory tests were retrospectively collected from patient
598 | www.annalsofsurgery.comrecords and the institutional trauma registry. The data included
admission vital signs, blood count test results, pH, base excess
(BE), conventional plasma based coagulation tests [prothrombin
time (PT), activated partial thromboplastin time (aPTT), inter-
national normalized ratio (INR)], prehospital fluids, 24-hour blood
transfusions (packed RBCs, plasma, and apheresis platelets), 24-hour
crystalloid infusions, complications, injury severity score (ISS), and
patient outcomes (mortality up to 28 days).
Blood samples were collected in citrated tubes from each
patient immediately upon hospital admission. Patients from whom
blood samples could not be obtained were excluded from analysis.
Upon hospital admission, 20mL of blood was obtained. Blood was
transferred into vacutainer tubes containing 3.2% citrate and inverted
to ensure proper anticoagulation. After spinning, plasma was
aliquoted and frozen for later analysis. The enzyme linked immu-
nosorbent assay (ELISA) analyses were conducted by trained labora-
tory technicians, according to the manufactures recommendations
at the Hemostasis Research Laboratory, Section for Transfusion
Medicine, Capital Region Blood Bank, Copenhagen University
Hospital, Rigshospitalet, Copenhagen, Denmark.
ELISA
Soluble biomarkers of sympathoadrenal activation (adrena-
line, noradrenaline), endothelial cell activation (sE-selectin),29,30
endothelial glycocalyx (syndecan-1),15 and cell (thrombo-
modulin)29–31 damage were measured by commercially available
immunoassays in EDTA plasma according to the manufactures
recommendations. Adrenaline and noradrenaline (2-CAT ELISA,
Labor Diagnostica Nord GmbH & Co. KG, Nordhorn, Germany)
have lower limit of detection (LLD) 10 pg/mL (adrenaline, normal
reference <100 pg/mL) and 50 pg/mL (noradrenaline, normal refer-
ence <600 pg/mL), respectively. Syndecan-1 (Diaclone Nordic
Biosite, Copenhagen, Denmark) has LLD 4.94 ng/mL, soluble
thrombomodulin (sTM, Nordic Biosite, Copenhagen, Denmark)
has LLD 0.31 ng/mL, sE-selectin (IBL International GMBH, Ham-
burg, Germany) has LLD 0.3 ng/mL, and sVE-cadherin (R&D
Systems Europe, Ltd., Abingdon, UK) has LLD 0.113 ng/mL.
Statistics
Statistical analysis was performed using SAS 9.4 (SAS Insti-
tute Inc., Cary, NC) and SPSS 22 (IBMCorporation, NewYork, NY).
Simple correlations were investigated by Pearson correlations
with results displayed as the product-moment correlation coefficient
Pearson?s r (or r2) and P values. To investigate the independent
association between sympathoadrenal activation and endothelial
glycocalyx and cell damage (syndecan-1, thrombomodulin, and
sE-selectin), univariate and multivariate adjusted linear regression
analysis were performed, including variables that were either found
to correlate with or were expected to influence endothelial damage:
age, ISS, GCS, SBP, BE, platelet count, hemoglobin, prehospital
plasma, and administered prehospital fluids (Table 2). Results
are presented as regression coefficients (b) with 95% confidence
intervals (CI) and P values.
The predictive value of sympathoadrenal activation (adrena-
line, noradrenaline) and endothelial damage (syndecan-1, thrombo-
modulin) for<24-hour, 7-day, and 28-day mortality was investigated
by univariate and multivariate adjusted Cox proportional-hazards
models, the latter after adjusting for age, sex, ISS, GCS, BE, platelet
count, and hemoglobin. Data are presented as relative hazard ratio
(HR) with 95% CI, Walds x2 and P values. To reveal the influence of
missing values on the results, multiple imputation analysis (five
imputed dataset and a merge of these) were conducted and the linear
regression analysis and Cox proportional-hazards models wereer Health, Inc. All rights reserved.
repeated on imputed data. This did not change the results for any
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
Annals of Surgery  Volume 265, Number 3, March 2017 Endotheliopathy of Traumaof the analyses and results from the raw data are displayed in the
manuscript. Data are presented as medians with IQR or as n
(proportions). P values <0.05 were considered significant.RESULTS
Patients
A total of 424 patients were included in the current study
with a median age of 40 years, 77% were male, median ISS was
17, and 72% suffered from blunt injury (Table 1). Further details
on demography, injury severity and type, admission physiology,
biomarker levels, transfusions, and outcome are displayed in Copyright © 2016 Wolters Klu
Table 1.
TABLE 1. Demography, Injury Type and Severity, Admission Phy
Prospectively Enrolled Trauma Patients Admitted to a Level I Trau
Unit
Demography
N
Age yrs
Sex male [n (%)]
Race W / BL /H /Othe
Injury type and severity
MOI Blunt injury
ISS score
Severe TBI (AIS head 3) n (%)
GCS score
Transfer n (%)
Mode of Transport HEL/AMB/Othe
Admission physiology and biochemistry
SBP (ED) mmHg
BE (ED) mEq/L
pH (ED)
Platelet count (ED) 109/L
Hemoglobin (ED) g/dL
PT sec
INR ratio
aPTT sec
Biomarkers
Adrenaline pg/mL
Noradrenaline pg/mL
Syndecan-1 ng/mL
Thrombomodulin ng/mL
sE-selectin ng/mL
Transfusions
Transfused n (%)
RBC (prehospital) n (%)
Plasma (prehospital) n (%)
Platelets (prehospital) n (%)
Crystalloids (prehospital) n (%)
Crystalloids volume (prehospital) mL
Outcome
Hospital LOS days
ICU LOS days
Ventilator days
Mortality (<24 hrs) n (%)
Mortality (7days) n (%)
Mortality (28 days) n (%)
Data are presented as medians (IQR) or n (%).
AIS head >3.
AIS indicates Abbreviated Injury Score; AMB, ambulance; aPTT, activated partial throm
Coma Scale; H, Hispanics; HEL, helicopter; ICU, intensive care unit; INR, international norma
mechanism of injury; PH, prehospital; PT, prothrombin time; RBC, red blood cells; SBP, s
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.Sympathoadrenal Activation and Endothelial
Damage
To investigate the association between sympathoadrenal acti-
vation and endothelial damage, we investigated simple correlations
between catecholamine levels and biomarkers reflecting endothelial
damage followed by linear regression analysis.
By simple correlations, plasma adrenaline and noradrenaline
correlated with plasma syndecan-1 (r ¼ 0.38, P < 0.001 and r ¼
0.23, P < 0.001, respectively) whereas neither adrenaline nor nor-
adrenaline correlated with thrombomodulin (r ¼ 0.06, P ¼ 0.213
and r ¼ 0.07, P ¼ 0.149, respectively) or sE-selectin (r¼ –0.09,
P ¼ 0.094 and r¼ –0.01, P ¼ 0.886, respectively). When stratifying
patients according to injury type, the correlation between plasmawer Health, Inc. All rights reserved.
adrenaline and syndecan-1 levels persisted within in both blunt
siology, Biomarker Levels, Transfusions, and Outcome in 424
ma Centre in the United States
Median (IQR)
424
40 (27–55)
326 (76.9%)
rs 231 (54%) / 67 (16%) / 103 (24%) / 23 (6%)
306 (72%)
17 (9–26)
180 (42%)
12 (3–15)
168 (40%)
rs 238 (56%) / 168 (40%) / 18 (4%)
124 (106–142)
3 (-6–1)
7.32 (7.25–7.37)
220 (180–269)
13.1 (11.9–14.4)
14.2 (13.4–15.3)
1.1 (1–1.2)
29.2 (26.3–32.5)
162 (53–364)
848 (332–1501)
25 (13–60)
5.2 (3.84–7.19)
39 (23–58)
138 (61.1%)
38 (10.4%)
29 (7.9%)
0 (0%)
156 (39.6%)
0 (0–200)
5 (1–15)
1 (0–5)
1 (0–3)
19 (4.9%)
62 (16.1%)
73 (17.2%)
boplastin time; BE, base excess; BL, Blacks; ED, emergency department; GCS, Glascow
lized ratio; IQR, interquartile range; ISS, injury severity score; LOS, length of stay; MOI,
ystolic blood pressure; TBI, severe traumatic brain injury; W, Whites.
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injury patients.
By linear regression analysis, univariate predictors of higher
syndecan-1 were higher ISS and lower GCS, SBP, BE, platelet count
and hemoglobin, and prehospital plasma and higher adrenaline but in
the adjusted model, higher plasma adrenaline was the only inde-
pendent predictor of higher syndecan-1 levels (Table 2). Univariate
predictors of higher thrombomodulin were higher age and ISS
and lower BE and hemoglobin (whereas adrenaline was not)
but only higher age and lower hemoglobin were independent pre-
dictors of higher thrombomodulin (Table 2). We did not perform
linear regression analysis for sE-selectin as this biomarker neither
correlated with catecholamines nor were predictive for mortality
(see below).
As depicted in Figure 1, the combined highest level plasma
adrenaline, injury severity, shock, inhospital transfusion, and 28-day
mortality were associated with excessively increased syndecan-1
levels (Figure 1A–D).
Outcome
The predictive value of sympathoadrenal activation and endo-
thelial damage for mortality was investigated by univariate and
adjusted Cox proportional-hazards models.
In the Cox proportional-hazards analyses, higher age, higher
ISS, and lower GCS, BE and hemoglobin, and higher adrenaline,
noradrenaline (P ¼ 0.007, P ¼ 0.137, and P ¼ 0.032, respectively)
syndecan-1 and thrombomodulin levels were univariate predictors of
<24-hour, 7-day, and 28-day mortality. The only exceptions were
that GCS did not predict <24-hours mortality; noradrenaline did not
predict 7-day mortality and hemoglobin did not predict 7-day and
28-day mortality (Table 3). Plasma sE-selectin did not predict
mortality (data not shown).
In the adjusted models, only adrenaline and syndecan-1 were
independent biomarker predictors of early <24-hour mortality
together with age and BE (Table 3). Adrenaline, syndecan-1,
and thrombomodulin levels were independent predictors of 7-day
and 28-day mortality together with age (Table 3). In the adjusted
models, noradrenaline predicted <24-hours mortality (P ¼ 0.048)
but not 7-day or 28-day mortality (data not shown).
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SDISCUSSION
The main findings of the current study were that plasma
catecholamine levels at admission correlated with circulating levels
of syndecan-1, an endothelial glycocalyx constituent, and that adre-
naline levels independently predicted higher syndecan-1 levels—that
is, a surrogate marker of glycocalyx degradation (endotheliopathy of
trauma). Furthermore, admission adrenaline and syndecan-1 were
independent predictors of both early and late mortality.
The finding here of an independent association between
higher syndecan-1 levels and mortality of trauma patients under-
scores the importance of the state of the endothelium and its related
constituents for outcome in these critically ill patients, and is in
alignment with our previous findings in smaller cohorts of trauma
patients.16,17 The results are also in agreement with findings in other
patient groups facing acute critical illness. In a large cohort of
patients with varying degrees of sepsis, we found a dose-dependent
increase in syndecan-1 levels with increased sepsis severity and
mortality.26 Moreover, syndecan-1 was here independently associ-
ated with organ failure, such as hepatic and renal failure.26 In patients
with acute myocardial infarction, being an acute critical illness
though with minute tissue damage but where cardiogenic shock
have systemic manifestations, we also found that higher syndecan-1 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 1. 3-D plots displaying associ-
ations between plasma adrenaline, injury
severity, base excess, transfusions,
mortality, and plasma levels of endo-
thelial glycocalyx damage in 424 trauma
patients admitted to a Level I Trauma
Centre in the United States. Injury
severity score (ISS) were categorized into
four groups (ISS <9, ISS 9–15, ISS 16–
25, and ISS >25) and plasma adrenaline
were categorized into quartiles (Q1
28pg/mL (IQR 16–28), Q2 93pg/mL
(IQR 77–124), Q3 263pg/mL (IQR
217–316), and Q4 884pg/mL (IQR
659–1901). Transfusions refers to inhos-
pital transfusions (yes, no). The 3-D plots
display: (A) ISS, adrenaline quartile, and
syndecan-1 (ng/mL); (B) Base excess,
adrenaline quartile, and syndecan-
1 (ng/mL); (C) Transfusions, adrenaline
quartile, and syndecan-1 (ng/mL); and
(D) 28-day mortality, adrenaline quar-
tiles, and syndecan-1 (ng/mL).
Annals of Surgery  Volume 265, Number 3, March 2017 Endotheliopathy of Traumamortality at 30 days.27 From a pathophysiological and mechanistic
point of view, it could be speculated that the increased shedding of
glycocalyx results in an increased activation and damage of the
endothelial cells resulting in a prothrombotic phenotype that leads to
microvascular thrombosis and ensuing organ failure.8 Here, this is
supported by an independent association of the endothelial cellular
damage marker sTM and increased 7-day and 28-day mortality.
Johansen et al26 reported in patients with sepsis that the level of
sTM independently predicted organ failure of the liver and the
kidneys and multiorgan failure and mortality; and in resuscitated
out of hospital cardiac arrest patients, sTM was also a strong and
independent predictor of 30-day mortality.28 Moreover, loss of
endothelial integrity causes capillary leakage with fluid extravasa-
tion, hypotension and shock, and in the current study we found that
lower systolic blood pressure and BE were strongly associated with
circulating syndecan-1, supporting this notion.
Traumatic injury immediately activates the sympathoadrenal
system with release of large amounts of catecholamines that exert
widespread dose-dependent effects on metabolism and the vascular
system.32,33 We proposed that patients with excessive trauma
activation, the sympathoadrenal system becomes maladaptive and
contribute to organ damage.8 Thus, in high concentrations, catechol-
amines directly damage the endothelium resulting in local edema,
endothelial cell swelling, necrosis, and progressive deendotheliali-
zation.34 In the current study, we found that plasma catecholamines
correlated strongly with plasma syndecan-1 and higher adrenaline
was the only independent predictor of higher syndecan-1 levels.
Moreover, the combined highest level plasma adrenaline, injury
severity, and transfusions (and mortality) was associated with exces-
sively increased syndecan-1, confirming our previous findings
that sympathoadrenal activation is of critical importance for develop- Copyright © 2016 Wolters Klu
ment of traumatic endotheliopathy. Furthermore, adrenaline and
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.syndecan-1 were independent predictors of early <24-hours
mortality and late 7-day and 28-day mortality, whereas sTM only
independently predicted 7-day and 28-day mortality. The finding
here, of a strong correlation between levels of catecholamines upon
admission and outcome, is in alignment with findings from other
patient groups suffering from acute critical illness. In patients
resuscitated from out-of-hospital cardiac arrest, we reported that
high plasma adrenaline was associated with increased 7-day, 30-day,
and 180-day mortality.28 Similarly, in patients with acute myocardial
infarction, stratified into quartiles based on plasma adrenaline levels,
one quartile higher plasma adrenaline was independently associated
with both increased 30-day and long-term mortality.27 In patients
with varying degree of infection, including sepsis, we also found that
catecholamines together with syndecan-1 and sTM independently
predicted increased 28-day mortality.28
According to our proposed hypothesis, sympathoadrenal acti-
vation is a pivotal driver of the traumatic endotheliopathy, so
modulation of this response by limiting the catecholamine surge,
is expected to be beneficial for outcome in these patients. Interest-
ingly, Bukur et al35 recently reported that in 663 critically injured
patients (ISS25) admitted to the intensive care unit, those 98
patients receiving beta-blockers upon admission, had significantly
lower inhospital mortality (11% vs 19%, P ¼ 0.006). Stepwise
logistic regression identified beta-blocker use as an independent
protective factor for mortality these patients. Similarly, Cotton
et al36 reported that in patients with severe traumatic brain injury,
beta-blocker exposure before the trauma was associated with a
significant reduction in mortality, which was even more impressive,
considering that the group on beta-blocker therapy was older, more
severely injured, and had lower predicted survival than the compa-
rators.36 Together, these findings support that downstream effects ofwer Health, Inc. All rights reserved.
excessive sympathoadrenal activation may also be harmful in
www.annalsofsurgery.com | 601
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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beta-blockers may be beneficial in these patients.
The current study has important limitations inherent to its
design. Being an observational study precludes from cause and effect
conclusions but merely points towards significant associations that
requires further investigation. Moreover, as a single-center study, this
limits the generalizability of the results, although our findings here
support previous reports from independent trauma cohorts.16,18,19
Furthermore, the selection of biomarkers analyzed in this study does
not preclude that other markers may also be of importance for the
development and progression of traumatic endotheliopathy. Unique
for the current study 10% of the patients received transfusions
prehospital and the median prehospital crystalloid use was 0. This
may have influenced the levels of endothelial biomarkers at admis-
sion given that administration of crystalloids has been shown to
increase the circulating levels of these markers and contribute to
endothelial damage.
In conclusion, the finding of the current study supports the
critical role of endotheliopathy for outcome in severely traumatized
patients and that sympathoadrenal activation is an important driver of
this condition. Future randomized controlled trials investigating the
effect of sympathoadrenal modulation and endothelial protection and
repair are highly warranted.
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